Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2

Michael P. O'Connell, Katie Marchbank, Marie R. Webster, Alexander A. Valiga, Amanpreet Kaur, Adina Vultur, Ling Li, Meenhard Herlyn, Jessie Villanueva, Qin Liu, Xiangfan Yin, Sandy Widura, Janelle Nelson, Nivia Ruiz, Tura C. Camilli, Fred E. Indig, Keith T. Flaherty, Jennifer A. Wargo, Dennie T. Frederick, Zachary A. CooperSuresh Nair, Ravi K. Amaravadi, Lynn M. Schuchter, Giorgos C. Karakousis, Wei Xu, Xiaowei Xu, Ashani T. Weeraratna

Research output: Contribution to journalArticle

Abstract

An emerging concept in melanoma biology is that of dynamic, adaptive phenotype switching, where cells switch from a highly proliferative, poorly invasive phenotype to a highly invasive, less proliferative one. This switch may hold significant implications not just for metastasis, but also for therapy resistance. We demonstrate that phenotype switching and subsequent resistance can be guided by changes in expression of receptors involved in the noncanonical Wnt5A signaling pathway, ROR1 and ROR2. ROR1 and ROR2 are inversely expressed in melanomas and negatively regulate each other. Furthermore, hypoxia initiates a shift of ROR1-positive melanomas to a more invasive, ROR2-positive phenotype. Notably, this receptor switch induces a 10-fold decrease in sensitivity to BRAF inhibitors. In patients with melanoma treated with the BRAF inhibitor vemurafenib, Wnt5A expression correlates with clinical response and therapy resistance. These data highlight the fact that mechanisms that guide metastatic progression may be linked to those that mediate therapy resistance. SIGNIFICANCE: These data show for the first time that a single signaling pathway, the Wnt signaling pathway, can effectively guide the phenotypic plasticity of tumor cells, when primed to do so by a hypoxic microenvironment. Importantly, this increased Wnt5A signaling can give rise to a subpopulation of highly invasive cells that are intrinsically less sensitive to novel therapies for melanoma, and targeting the Wnt5A/ROR2 axis could improve the efficacy and duration of response for patients with melanoma on vemurafenib.

Original languageEnglish (US)
Pages (from-to)1378-1393
Number of pages16
JournalCancer discovery
Volume3
Issue number12
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Receptor Protein-Tyrosine Kinases
Melanoma
Phenotype
Therapeutics
Wnt Signaling Pathway
Hypoxia
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. / O'Connell, Michael P.; Marchbank, Katie; Webster, Marie R.; Valiga, Alexander A.; Kaur, Amanpreet; Vultur, Adina; Li, Ling; Herlyn, Meenhard; Villanueva, Jessie; Liu, Qin; Yin, Xiangfan; Widura, Sandy; Nelson, Janelle; Ruiz, Nivia; Camilli, Tura C.; Indig, Fred E.; Flaherty, Keith T.; Wargo, Jennifer A.; Frederick, Dennie T.; Cooper, Zachary A.; Nair, Suresh; Amaravadi, Ravi K.; Schuchter, Lynn M.; Karakousis, Giorgos C.; Xu, Wei; Xu, Xiaowei; Weeraratna, Ashani T.

In: Cancer discovery, Vol. 3, No. 12, 01.12.2013, p. 1378-1393.

Research output: Contribution to journalArticle

O'Connell, MP, Marchbank, K, Webster, MR, Valiga, AA, Kaur, A, Vultur, A, Li, L, Herlyn, M, Villanueva, J, Liu, Q, Yin, X, Widura, S, Nelson, J, Ruiz, N, Camilli, TC, Indig, FE, Flaherty, KT, Wargo, JA, Frederick, DT, Cooper, ZA, Nair, S, Amaravadi, RK, Schuchter, LM, Karakousis, GC, Xu, W, Xu, X & Weeraratna, AT 2013, 'Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2', Cancer discovery, vol. 3, no. 12, pp. 1378-1393. https://doi.org/10.1158/2159-8290.CD-13-0005
O'Connell, Michael P. ; Marchbank, Katie ; Webster, Marie R. ; Valiga, Alexander A. ; Kaur, Amanpreet ; Vultur, Adina ; Li, Ling ; Herlyn, Meenhard ; Villanueva, Jessie ; Liu, Qin ; Yin, Xiangfan ; Widura, Sandy ; Nelson, Janelle ; Ruiz, Nivia ; Camilli, Tura C. ; Indig, Fred E. ; Flaherty, Keith T. ; Wargo, Jennifer A. ; Frederick, Dennie T. ; Cooper, Zachary A. ; Nair, Suresh ; Amaravadi, Ravi K. ; Schuchter, Lynn M. ; Karakousis, Giorgos C. ; Xu, Wei ; Xu, Xiaowei ; Weeraratna, Ashani T. / Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. In: Cancer discovery. 2013 ; Vol. 3, No. 12. pp. 1378-1393.
@article{23a2cfae0c9b4f0c9c874eb2def1a944,
title = "Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2",
abstract = "An emerging concept in melanoma biology is that of dynamic, adaptive phenotype switching, where cells switch from a highly proliferative, poorly invasive phenotype to a highly invasive, less proliferative one. This switch may hold significant implications not just for metastasis, but also for therapy resistance. We demonstrate that phenotype switching and subsequent resistance can be guided by changes in expression of receptors involved in the noncanonical Wnt5A signaling pathway, ROR1 and ROR2. ROR1 and ROR2 are inversely expressed in melanomas and negatively regulate each other. Furthermore, hypoxia initiates a shift of ROR1-positive melanomas to a more invasive, ROR2-positive phenotype. Notably, this receptor switch induces a 10-fold decrease in sensitivity to BRAF inhibitors. In patients with melanoma treated with the BRAF inhibitor vemurafenib, Wnt5A expression correlates with clinical response and therapy resistance. These data highlight the fact that mechanisms that guide metastatic progression may be linked to those that mediate therapy resistance. SIGNIFICANCE: These data show for the first time that a single signaling pathway, the Wnt signaling pathway, can effectively guide the phenotypic plasticity of tumor cells, when primed to do so by a hypoxic microenvironment. Importantly, this increased Wnt5A signaling can give rise to a subpopulation of highly invasive cells that are intrinsically less sensitive to novel therapies for melanoma, and targeting the Wnt5A/ROR2 axis could improve the efficacy and duration of response for patients with melanoma on vemurafenib.",
author = "O'Connell, {Michael P.} and Katie Marchbank and Webster, {Marie R.} and Valiga, {Alexander A.} and Amanpreet Kaur and Adina Vultur and Ling Li and Meenhard Herlyn and Jessie Villanueva and Qin Liu and Xiangfan Yin and Sandy Widura and Janelle Nelson and Nivia Ruiz and Camilli, {Tura C.} and Indig, {Fred E.} and Flaherty, {Keith T.} and Wargo, {Jennifer A.} and Frederick, {Dennie T.} and Cooper, {Zachary A.} and Suresh Nair and Amaravadi, {Ravi K.} and Schuchter, {Lynn M.} and Karakousis, {Giorgos C.} and Wei Xu and Xiaowei Xu and Weeraratna, {Ashani T.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1158/2159-8290.CD-13-0005",
language = "English (US)",
volume = "3",
pages = "1378--1393",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2

AU - O'Connell, Michael P.

AU - Marchbank, Katie

AU - Webster, Marie R.

AU - Valiga, Alexander A.

AU - Kaur, Amanpreet

AU - Vultur, Adina

AU - Li, Ling

AU - Herlyn, Meenhard

AU - Villanueva, Jessie

AU - Liu, Qin

AU - Yin, Xiangfan

AU - Widura, Sandy

AU - Nelson, Janelle

AU - Ruiz, Nivia

AU - Camilli, Tura C.

AU - Indig, Fred E.

AU - Flaherty, Keith T.

AU - Wargo, Jennifer A.

AU - Frederick, Dennie T.

AU - Cooper, Zachary A.

AU - Nair, Suresh

AU - Amaravadi, Ravi K.

AU - Schuchter, Lynn M.

AU - Karakousis, Giorgos C.

AU - Xu, Wei

AU - Xu, Xiaowei

AU - Weeraratna, Ashani T.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - An emerging concept in melanoma biology is that of dynamic, adaptive phenotype switching, where cells switch from a highly proliferative, poorly invasive phenotype to a highly invasive, less proliferative one. This switch may hold significant implications not just for metastasis, but also for therapy resistance. We demonstrate that phenotype switching and subsequent resistance can be guided by changes in expression of receptors involved in the noncanonical Wnt5A signaling pathway, ROR1 and ROR2. ROR1 and ROR2 are inversely expressed in melanomas and negatively regulate each other. Furthermore, hypoxia initiates a shift of ROR1-positive melanomas to a more invasive, ROR2-positive phenotype. Notably, this receptor switch induces a 10-fold decrease in sensitivity to BRAF inhibitors. In patients with melanoma treated with the BRAF inhibitor vemurafenib, Wnt5A expression correlates with clinical response and therapy resistance. These data highlight the fact that mechanisms that guide metastatic progression may be linked to those that mediate therapy resistance. SIGNIFICANCE: These data show for the first time that a single signaling pathway, the Wnt signaling pathway, can effectively guide the phenotypic plasticity of tumor cells, when primed to do so by a hypoxic microenvironment. Importantly, this increased Wnt5A signaling can give rise to a subpopulation of highly invasive cells that are intrinsically less sensitive to novel therapies for melanoma, and targeting the Wnt5A/ROR2 axis could improve the efficacy and duration of response for patients with melanoma on vemurafenib.

AB - An emerging concept in melanoma biology is that of dynamic, adaptive phenotype switching, where cells switch from a highly proliferative, poorly invasive phenotype to a highly invasive, less proliferative one. This switch may hold significant implications not just for metastasis, but also for therapy resistance. We demonstrate that phenotype switching and subsequent resistance can be guided by changes in expression of receptors involved in the noncanonical Wnt5A signaling pathway, ROR1 and ROR2. ROR1 and ROR2 are inversely expressed in melanomas and negatively regulate each other. Furthermore, hypoxia initiates a shift of ROR1-positive melanomas to a more invasive, ROR2-positive phenotype. Notably, this receptor switch induces a 10-fold decrease in sensitivity to BRAF inhibitors. In patients with melanoma treated with the BRAF inhibitor vemurafenib, Wnt5A expression correlates with clinical response and therapy resistance. These data highlight the fact that mechanisms that guide metastatic progression may be linked to those that mediate therapy resistance. SIGNIFICANCE: These data show for the first time that a single signaling pathway, the Wnt signaling pathway, can effectively guide the phenotypic plasticity of tumor cells, when primed to do so by a hypoxic microenvironment. Importantly, this increased Wnt5A signaling can give rise to a subpopulation of highly invasive cells that are intrinsically less sensitive to novel therapies for melanoma, and targeting the Wnt5A/ROR2 axis could improve the efficacy and duration of response for patients with melanoma on vemurafenib.

UR - http://www.scopus.com/inward/record.url?scp=84890063283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890063283&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-13-0005

DO - 10.1158/2159-8290.CD-13-0005

M3 - Article

C2 - 24104062

AN - SCOPUS:84890063283

VL - 3

SP - 1378

EP - 1393

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 12

ER -